Sort   by:  
 Page size 
UnknownObservational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.
Not available
S-EPMC9123044 | biostudies-literature
UnknownNeoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Not available
S-EPMC4304382 | biostudies-literature
Unknown18F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study.
Not available
S-EPMC12781833 | biostudies-literature
UnknownActionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.
Not available
S-EPMC6854749 | biostudies-literature
UnknownEfficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial.
Not available
S-EPMC8063137 | biostudies-literature
UnknownPredictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
Not available
S-EPMC7078275 | biostudies-literature
UnknownGEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers.
Not available
S-EPMC6220051 | biostudies-literature
UnknownCalibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using <i>BRCA2</i> Exon 3 as a Model System.
Not available
S-EPMC7484206 | biostudies-literature
UnknownGene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility.
Not available
S-EPMC9290690 | biostudies-literature
GenomicsMELARISK Data Access Committee
Access to data generated by the MELARISK is available by emailing application to the data access committee and will be granted to qualified investigators for appropriate use.
EGAC00000000016 | EGA
Sort   by:  
 Page size